NCT03713658: A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities |
|
|
| Completed | 4 | 34 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen Research & Development, LLC | Schizophrenia | 12/19 | 12/19 | | |
CASPAR, NCT04940039: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings |
|
|
| Completed | 4 | 93 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen-Cilag International NV | Schizophrenia | 04/24 | 04/24 | | |